UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

FORM 8-K

_____________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 12, 2019

  TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)   001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.)

   2 Gansevoort Street, 9th Floor

New York, New York 10014

(Address of Principal Executive Offices)

(212) 554-4484

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

       ☐ Written communications pursuant to Rule 425 under the Securities Act.

       ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

       ☐ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

       ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Title of Class	Trading Symbol(s)	Exchange Name
Common Stock, par value $0.001	TGTX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 12, 2019, TG Therapeutics, Inc. (“TG” or the “Company”) presented the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for Ublituximab (TG-1101), the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Stockholm, Sweden. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

 

Item 9.01 Financial Statements And Exhibits.

(d)          Exhibits.

99.1
Press release issued by TG Therapeutics, Inc., dated September 12, 2019.

            SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TG Therapeutics, Inc. (Registrant)
Date: September 12, 2019	By:	/s/ Sean A. Power
		Sean A. Power
		Chief Financial Officer